
Claims:

1. Use of a compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof, in the manufacture of a medicament for the treatment of depression in a subject, wherein the medicament is to be administered to the subject in need of such treatment:



(I)

wherein:

R_1 is C_{1-4} alkyl;

R_2 is C_{1-4} alkyl;

R_3 is H or halogen; and

R_4 is H or C_{1-4} alkoxy;

wherein the medicamdnt is to be administered prior to sleep.

2. The use according to claim 1 wherein the subject is not suffering from or diagnosed with an insomnia disorder.

3. The use according to claim 1, wherein

R^3 is halogen, optionally fluorine.

4. The use according to claim 1, wherein R^4 is H.

5. The use according to claim 1, wherein R^4 is C_{1-4}alkoxy, optionally methoxy.

6. The use according to claim 1, wherein R^3 is H.

7. The use according to claim 1, wherein R^1 is CH_3.

8. The use according to claim 1, wherein R^2 is CH_3.

9. The use according to claim 1, wherein the compound is 5-(4,6-dimethyl-pyrimidin-2-yl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-(2-fluoro-6-[1,2,3]triazol-2-yl-phenyl)-methanone or a pharmaceutically acceptable salt thereof.

10. The use according to claim 1, wherein the compound is 5-(4,6-dimethyl-pyrimidin-2-yl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-(2-fluoro-6-[1,2,3]triazol-2-yl-phenyl)-methanone.

11. The use according to claim 1, wherein the compound is 5-(4,6-dimethyl-pyrimidin-2-yl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-(2-fluoro-6-[1,2,3]triazol-2-yl-phenyl)-methanone hydrochloride.

12. The use according to claim 1, wherein the compound is (5-(4,6-dimethylpyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)(4-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone or a pharmaceutically acceptable salt thereof.

13. The use according to claim 1, wherein the compound is (5-(4,6-dimethylpyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)(4-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.

14. The use according to claim 1, wherein the compound is to be administered at night.

15. The use according to claim 1, wherein the compound is to be administered at daily.

16. The use according to claim 1, wherein the compound is to be administered orally.

17. The use according to claim 1, wherein the effective amount is 10 to 40 mg.

18. The use according to claim 1, wherein the depression comprises major depressive disorder, depression associated with bipolar disease, or treatment resistant depression, optionally wherein the depression is major depressive disorder or treatment resistant depression.

19. The use according to claim 1, wherein a second antidepressant is to be administered to the subject, optionally wherein said second antidepressant is a selective serotonin reuptake inhibitor, serotonin and noradrenaline reuptake inhibitor, or combinations thereof.

20. The use according to claim 9, wherein the subject is not

suffering from or diagnosed with an insomnia disorder.

21. The use according to claim 9 or 20, wherein the compound is to be administered at night.

22. The use according to any one of claims 9, 20 or 21, wherein the depression is major depressive disorder.

23. The use according any one of claims 9 or 20-22, wherein a second antidepressant is to be administered to the subject.

24. The use according to claim 23, wherein the second antidepressant is a selective serotonin reuptake inhibitor, serotonin and noradrenaline reuptake inhibitor, or combinations thereof.

25. The use according to claim 23 or 24, wherein the effective amount of the compound is 10 to 40 mg.

26. The use according to claim 23 or 24, wherein the effective amount of the compound is about 20 mg.

27. The use according to claim 25 or 26, wherein the compound is to be administered once daily.

28. The use according to any one of the preceding claims, wherein the medicament is intended to treat a psychic symptom of the depression.